WEDNESDAY, Aug. 15, 2018 -- For women with advanced breast cancer who carry the BRCA1 and BRCA2 gene mutations, an experimental drug could improve survival, a new study suggests.
The BRCA mutations are linked with a greater risk for aggressive breast and ovarian cancer. The drug, talazoparib, works by blocking an enzyme called poly ADP ribose polymerase (PARP), thus preventing cancer cells from killing healthy ones.
WEDNESDAY, June 20, 2018 -- For women who have their breast removed while fighting cancer, using their own tissue for breast reconstruction is better than implants, a new study suggests.
More than 60 percent of women who undergo breast removal to treat breast cancer decide to have breast reconstruction, and that rate is rising. But the researchers said that there has been little information about long-term satisfaction and quality of life after breast reconstruction.